✦ LIBER ✦

Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial

✍ Scribed by Dieke H. J. Kok; Ralph J. B. Sakkers; Arieke J. Janse; Hans E. H. Pruijs; Ab J. Verbout; Rene M. Castelein; Raoul H. H. Engelbert

Book ID: 111707197
Publisher: Springer
Year: 2007
Tongue: English
Weight: 136 KB
Volume: 166
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00431-006-0399-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Skeletal effects and functional outcome

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

✍ Ralph Sakkers; Dieke Kok; Raoul Engelbert; Alice van Dongen; Maarten Jansen; Han 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 86 KB

Effects of Oral Alendronate on BMD in Ad

Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3-Year Randomized Placebo-Controlled Trial

✍ Guillaume Chevrel; Anne-Marie Schott; Elisabeth Fontanges; Jeanne E Charrin; Gen 📂 Article 📅 2005 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 116 KB

(739/Paper 318): A randomized double-bli

(739/Paper 318): A randomized double-blind placebo controlled trial assessing the effect of the oral cannabinoid nabilone on pain and quality of life in patients with fibromyalgia

✍ R. Skrabek; L. Galimova 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Impact of ustekinumab on health-related

Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB

P01-37 Dose sparing effect of an IGF-I-b

P01-37 Dose sparing effect of an IGF-I-based dosing regimen in short children treated with Growth Hormone in a 2-Year randomized controlled trial: Therapeutic and pharmacoeconomic considerations

✍ Cohen, P.; Rogol, A.D.; Weng, W.; Kappelgaard, A.-M.; Rosenfeld, R.G.; Germak, J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB